



The Tumor Microenvironment (TME) – Part 1



TME Hallmarks:



<p>FABP4 antibody [HL1521] (GTx636995)</p>	<p>STAT3 (phospho Tyr705) antibody [HL1464] (GTx636938)</p>	<p>VEGFA antibody [HL1755] (GTx637405)</p>
<p>Fatty Acid Synthase antibody [HL2161] (GTx638139)</p>	<p>beta Catenin antibody [HL1753] (GTx637403)</p>	<p>CD8+ T cells Glycolysis ↓ Lipid uptake ↑ Lipid accumulation ↑ Fatty acid oxidation ↑</p>
<p>IDH1 (R132H Mutant) antibody [HL4884] (GTx644949)</p>	<p>NFkB p65 antibody [HL4229] (GTx643062)</p>	<p>CD8+ T cells Glycolysis ↓ Lipid uptake ↑ Lipid accumulation ↑ Fatty acid oxidation ↑</p>
<p>Heme Oxygenase 1 antibody [HL1780] (GTx637432)</p>	<p>mTOR antibody [HL2216] (GTx638220)</p>	<p>CD8+ T cells Glycolysis ↓ Lipid uptake ↑ Lipid accumulation ↑ Fatty acid oxidation ↑</p>



References:

1. *Signal Transduct Target Ther.* 2023 Feb 17;8(1):70.
2. *Sci Adv.* 2016 May 27;2(15):e1600200.
3. *Cancer Biol Med.* 2022 Oct 24;19(11):1528-1542.
4. *J Hematol Oncol.* 2023 Sep 12;16(1):103.
5. *Nat Rev Cancer.* 2016 Nov;16(11):732-749.

